Equity Profile

ERAS

Erasca, Inc.

Health CareBiotechnology$6.2B

Aug12Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Erasca, Inc. is a biotechnology company focused on developing innovative cancer therapies....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and validate its product pipeline.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ERAS Q2-2026 Earnings Preview

Context

Company Snapshot

Erasca, Inc. is a biotechnology company focused on developing innovative cancer therapies. With a market cap of $6 billion, it operates in the Health Care sector, addressing significant medical needs in oncology through targeted treatments.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

-29.90%

Avg Stock Reaction

+1.89%

Last Quarter Recap

In Q1-2026, Erasca reported an EPS of -$0.60, missing estimates by a significant margin. Despite the disappointing results, the stock rose by 3.16% the following day, indicating some investor optimism.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Erasca's upcoming earnings are mixed, with no analyst estimates available to guide sentiment. Investors are particularly focused on any updates regarding clinical trials and revenue growth.

Bull Case

If Erasca can demonstrate significant progress in its clinical trials and show revenue growth, it could validate its business model and lead to a strong stock performance.

Bear Case

Conversely, if the company continues to miss EPS estimates and fails to provide positive updates on its drug pipeline, it could lead to a decline in investor confidence and stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What updates will be provided on the progress of ongoing clinical trials?

Investors will closely watch for any advancements or setbacks in clinical trials, as these can significantly impact the company's future prospects.

How does the company plan to address the recent EPS misses?

Understanding management's strategy to improve profitability will be crucial for investor confidence and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Erasca's pipeline to deliver breakthrough results, which could lead to a more favorable reception than anticipated.

Supporting Evidence

The stock has historically reacted positively to clinical trial updates, suggesting that any positive news could drive significant interest.

Options pricing indicates a high level of uncertainty, which could mean that any positive news may lead to outsized gains.

Key Risk

If the company can provide solid updates on its clinical trials, it could shift the narrative and lead to a strong rebound in stock price.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it will reveal whether Erasca can turn around its recent disappointing results and regain investor confidence.

Bull Confirmed If

Demonstrating a clear path to profitability with a reduction in EPS losses and positive trial updates would confirm the bull case.

Bear Confirmed If

Continued significant EPS misses and lack of progress in clinical trials would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±42.13%

Historical Avg

±5.3%

Pricing rich

The options market is pricing in a significant potential move in either direction, indicating heightened uncertainty ahead of the earnings report.

Options are pricing ±42.1% while ERAS has averaged ±5.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

215.7%

Calls (25K)P/C Ratio: 0.16Puts (5K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Erasca beats expectations and raises guidance, history suggests the stock could see a modest increase, potentially confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may experience a muted reaction as investors weigh future prospects.

Miss

Should the company miss expectations again, history suggests a more significant decline in stock price, reflecting ongoing concerns about its financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any specific updates on the timelines for clinical trial results.
2Management's commentary on strategies to improve EPS moving forward.
3Insights into the competitive landscape and how Erasca plans to differentiate its products.
4Details on any partnerships or collaborations that could enhance growth prospects.
5Feedback from analysts on the market's reception of the earnings report.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug10

BWBMO

Babcock & Wilcox Enterprises, Inc.

PreviewView

Aug10

ROIVBMO

Company Snapshot

Erasca, Inc. is a biotechnology company focused on developing innovative cancer therapies....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and validate its product pipeline.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ERAS Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

-29.90%

Avg Stock Reaction

+1.89%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Erasca can demonstrate significant progress in its clinical trials and show revenue growth, it could validate its business model and lead to a strong stock performance.

Bear Case

Conversely, if the company continues to miss EPS estimates and fails to provide positive updates on its drug pipeline, it could lead to a decline in investor confidence and stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What updates will be provided on the progress of ongoing clinical trials?

Investors will closely watch for any advancements or setbacks in clinical trials, as these can significantly impact the company's future prospects.

How does the company plan to address the recent EPS misses?

Understanding management's strategy to improve profitability will be crucial for investor confidence and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Erasca's pipeline to deliver breakthrough results, which could lead to a more favorable reception than anticipated.

Supporting Evidence

The stock has historically reacted positively to clinical trial updates, suggesting that any positive news could drive significant interest.

Options pricing indicates a high level of uncertainty, which could mean that any positive news may lead to outsized gains.

Key Risk

If the company can provide solid updates on its clinical trials, it could shift the narrative and lead to a strong rebound in stock price.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it will reveal whether Erasca can turn around its recent disappointing results and regain investor confidence.

Bull Confirmed If

Demonstrating a clear path to profitability with a reduction in EPS losses and positive trial updates would confirm the bull case.

Bear Confirmed If

Continued significant EPS misses and lack of progress in clinical trials would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±42.13%

Historical Avg

±5.3%

Pricing rich

The options market is pricing in a significant potential move in either direction, indicating heightened uncertainty ahead of the earnings report.

Options are pricing ±42.1% while ERAS has averaged ±5.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

215.7%

Calls (25K)P/C Ratio: 0.16Puts (5K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Erasca beats expectations and raises guidance, history suggests the stock could see a modest increase, potentially confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may experience a muted reaction as investors weigh future prospects.

Miss

Should the company miss expectations again, history suggests a more significant decline in stock price, reflecting ongoing concerns about its financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any specific updates on the timelines for clinical trial results.
2Management's commentary on strategies to improve EPS moving forward.
3Insights into the competitive landscape and how Erasca plans to differentiate its products.
4Details on any partnerships or collaborations that could enhance growth prospects.
5Feedback from analysts on the market's reception of the earnings report.